Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group, Susanna Naggie
doi: https://doi.org/10.1101/2022.06.10.22276252
1Duke Clinical Research Institute, Duke University School of Medicine
Susanna Naggie
1Duke Clinical Research Institute, Duke University School of Medicine
MD, MHS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: susanna.naggie@duke.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The effectiveness of ivermectin to shorten symptom duration or prevent hospitalization among outpatients in the United States with mild-to-moderate symptomatic coronavirus disease 2019 (COVID-19) is unknown.

Objective We evaluated the efficacy of ivermectin 400 µg/kg daily for 3 days compared with placebo for the treatment of early mild-to-moderate COVID-19.

Methods ACTIV-6 is an ongoing, decentralized, double-blind, randomized, placebo-controlled platform trial to evaluate repurposed therapies in outpatients with mild-to-moderate COVID-19. Non-hospitalized adults age ≥30 years with confirmed COVID-19, experiencing ≥2 symptoms of acute infection for ≤7 days were randomized to receive ivermectin 400 µg/kg daily for 3 days or placebo. The main outcome measure was time to sustained recovery, defined as achieving at least 3 consecutive days without symptoms. Secondary outcomes included a composite of hospitalization or death by day 28.

Results Of the 3457 participants who consented to be evaluated for inclusion in the ivermectin arm, 1591 were eligible for this study arm, randomized to receive ivermectin 400 µg/kg (n=817) or placebo (n=774), and received study drug. Of those enrolled, 47% reported receiving at least 2 doses of SARS-CoV-2 vaccination. The posterior probability for any improvement in time to recovery was 0.91 (hazard ratio 1.07, 95% credible interval 0.96–1.17). The posterior probability of this benefit exceeding 24 hours was less than 0.01, as measured by the difference in mean time unwell. Hospitalizations or deaths were uncommon (ivermectin [n=10]; placebo [n=9]). Ivermectin at 400 µg/kg was safe and without serious adverse events as compared with placebo (ivermectin [n=10]; placebo [n=9]).

Conclusions Ivermectin dosed at 400 µg/kg daily for 3 days resulted in less than one day of shortening of symptoms and did not lower incidence of hospitalization or death among outpatients with COVID-19 in the United States during the delta and omicron variant time periods.

Trial registration ClinicalTrials.gov Identifier: NCT04885530.

Competing Interest Statement

Authorship is attributed to the ACTIV-6 Study Group. Funding information for the ACTIV-6 study is included in the manuscript.

Clinical Trial

NCT04885530

Funding Statement

ACTIV-6 is funded by the National Center for Advancing Translational Sciences (NCATS) (3U24TR001608-05W1). This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No.75A50122C00037.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

WCG IRB gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • The funding statement has been updated.

Data Availability

Prior to deposition of the data in a public repository which will occur when the platform trial has concluded, persons may request the data by submitting a proposal. If the data can be used for the proposed purpose and it is consistent with the informed consent, then the data will be released under a Data Use Agreement.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 11, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group, Susanna Naggie
medRxiv 2022.06.10.22276252; doi: https://doi.org/10.1101/2022.06.10.22276252
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group, Susanna Naggie
medRxiv 2022.06.10.22276252; doi: https://doi.org/10.1101/2022.06.10.22276252

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (552)
  • Anesthesia (135)
  • Cardiovascular Medicine (1752)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (657)
  • Epidemiology (10792)
  • Forensic Medicine (8)
  • Gastroenterology (586)
  • Genetic and Genomic Medicine (2941)
  • Geriatric Medicine (287)
  • Health Economics (532)
  • Health Informatics (1921)
  • Health Policy (835)
  • Health Systems and Quality Improvement (745)
  • Hematology (291)
  • HIV/AIDS (628)
  • Infectious Diseases (except HIV/AIDS) (12510)
  • Intensive Care and Critical Care Medicine (687)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2791)
  • Nursing (151)
  • Nutrition (432)
  • Obstetrics and Gynecology (558)
  • Occupational and Environmental Health (597)
  • Oncology (1460)
  • Ophthalmology (443)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (363)
  • Primary Care Research (336)
  • Psychiatry and Clinical Psychology (2636)
  • Public and Global Health (5350)
  • Radiology and Imaging (1009)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (726)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)